RLMD
Price
$3.21
Change
-$0.09 (-2.73%)
Updated
Nov 13 closing price
131 days until earnings call
SYRE
Price
$32.98
Change
-$2.84 (-7.93%)
Updated
Nov 13 closing price
105 days until earnings call
Ad is loading...

RLMD vs SYRE

Header iconRLMD vs SYRE Comparison
Open Charts RLMD vs SYREBanner chart's image
Relmada Therapeutics
Price$3.21
Change-$0.09 (-2.73%)
Volume$108.25K
CapitalizationN/A
Spyre Therapeutics
Price$32.98
Change-$2.84 (-7.93%)
Volume$793.6K
CapitalizationN/A
RLMD vs SYRE Comparison Chart
Loading...
RLMD
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
RLMD vs. SYRE commentary
Nov 14, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RLMD is a StrongSell and SYRE is a Hold.

COMPARISON
Comparison
Nov 14, 2024
Stock price -- (RLMD: $3.22 vs. SYRE: $32.97)
Brand notoriety: RLMD and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RLMD: 51% vs. SYRE: 150%
Market capitalization -- RLMD: $97.16M vs. SYRE: $1.7B
RLMD [@Biotechnology] is valued at $97.16M. SYRE’s [@Biotechnology] market capitalization is $1.7B. The market cap for tickers in the [@Biotechnology] industry ranges from $473.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.76B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RLMD’s FA Score shows that 1 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • RLMD’s FA Score: 1 green, 4 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, both RLMD and SYRE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RLMD’s TA Score shows that 4 TA indicator(s) are bullish while SYRE’s TA Score has 4 bullish TA indicator(s).

  • RLMD’s TA Score: 4 bullish, 5 bearish.
  • SYRE’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, RLMD is a better buy in the short-term than SYRE.

Price Growth

RLMD (@Biotechnology) experienced а -5.29% price change this week, while SYRE (@Biotechnology) price change was -12.02% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.97%. For the same industry, the average monthly price growth was +5.49%, and the average quarterly price growth was +6.49%.

Reported Earning Dates

RLMD is expected to report earnings on Mar 25, 2025.

SYRE is expected to report earnings on Feb 27, 2025.

Industries' Descriptions

@Biotechnology (-1.97% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($1.7B) has a higher market cap than RLMD($97.2M). SYRE YTD gains are higher at: 53.230 vs. RLMD (-22.222). RLMD has higher annual earnings (EBITDA): -91.33M vs. SYRE (-172.92M). SYRE has more cash in the bank: 426M vs. RLMD (70.4M). SYRE has less debt than RLMD: SYRE (0) vs RLMD (256K). RLMD (0) and SYRE (0) have equivalent revenues.
RLMDSYRERLMD / SYRE
Capitalization97.2M1.7B6%
EBITDA-91.33M-172.92M53%
Gain YTD-22.22253.230-42%
P/E RatioN/A3.03-
Revenue00-
Total Cash70.4M426M17%
Total Debt256K0-
FUNDAMENTALS RATINGS
RLMD vs SYRE: Fundamental Ratings
RLMD
SYRE
OUTLOOK RATING
1..100
8215
VALUATION
overvalued / fair valued / undervalued
1..100
32
Undervalued
79
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
4836
P/E GROWTH RATING
1..100
10036
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RLMD's Valuation (32) in the null industry is somewhat better than the same rating for SYRE (79) in the Pharmaceuticals Major industry. This means that RLMD’s stock grew somewhat faster than SYRE’s over the last 12 months.

RLMD's Profit vs Risk Rating (100) in the null industry is in the same range as SYRE (100) in the Pharmaceuticals Major industry. This means that RLMD’s stock grew similarly to SYRE’s over the last 12 months.

RLMD's SMR Rating (97) in the null industry is in the same range as SYRE (100) in the Pharmaceuticals Major industry. This means that RLMD’s stock grew similarly to SYRE’s over the last 12 months.

SYRE's Price Growth Rating (36) in the Pharmaceuticals Major industry is in the same range as RLMD (48) in the null industry. This means that SYRE’s stock grew similarly to RLMD’s over the last 12 months.

SYRE's P/E Growth Rating (36) in the Pharmaceuticals Major industry is somewhat better than the same rating for RLMD (100) in the null industry. This means that SYRE’s stock grew somewhat faster than RLMD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RLMDSYRE
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
87%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
84%
MACD
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 24 days ago
83%
Bullish Trend 7 days ago
84%
Declines
ODDS (%)
Bearish Trend 10 days ago
82%
Bearish Trend 1 day ago
89%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
RLMD
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WWSAX27.56N/A
N/A
TETON Westwood SmallCap Equity A
BIECX21.04N/A
N/A
Brandes International Equity C
JANEX155.21-0.22
-0.14%
Janus Henderson Enterprise D
DRISX23.71-0.21
-0.88%
Foundry Partners Sm Cp Val Instl
QFVOX23.40-0.22
-0.93%
Pear Tree Polaris Foreign Value Ord

RLMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, RLMD has been loosely correlated with SYRE. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if RLMD jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RLMD
1D Price
Change %
RLMD100%
-2.42%
SYRE - RLMD
36%
Loosely correlated
-7.94%
ENTO - RLMD
36%
Loosely correlated
+1.61%
ALVR - RLMD
35%
Loosely correlated
+4.04%
SCPX - RLMD
34%
Loosely correlated
-7.48%
PRTC - RLMD
31%
Poorly correlated
-4.73%
More

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with SNPX. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then SNPX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
-7.94%
SNPX - SYRE
47%
Loosely correlated
-8.73%
PMN - SYRE
44%
Loosely correlated
N/A
TCRX - SYRE
42%
Loosely correlated
-2.77%
GOSS - SYRE
41%
Loosely correlated
-3.66%
MLTX - SYRE
41%
Loosely correlated
-1.60%
More